Publication: Healthcare Brew
The article explores the anticipated developments in psychedelic medicine for 2025 following the FDA’s rejection of Lykos’ MDMA-based therapy in 2024. Industry players now aim to recalibrate clinical trials to address FDA concerns and generate reliable data. Thought leaders like Certara’s Dr. Fran Brown highlighted why companies developing psychedelic medicines should focus on learning from Lykos’s missteps.
Year: January 13, 2025
Solutions
Learn more about Clinical Pharmacology Regulatory Strategy
Connect with our team to discuss how Certara’s Clinical Pharmacology Regulatory Strategy can optimize your drug development program. We’re here to provide expert guidance tailored to your unique challenges.
